Combination of an ACLY Inhibitor with a GLP-1R Agonist Exerts Additive Benefits on Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Mice

Investigators found that combining an inhibitor of liver ATP citrate lyase (ACLY), bempedoic acid, and the GLP-1R agonist liraglutide reduced liver steatosis, hepatocellular ballooning, and hepatic fibrosis in a mouse model of nonalcoholic steatohepatitis.